Interactions between ß 1 and ß 2 adrenergic receptor polymorphisms as risk factors for chronic heart failure;Interacción entre los polimorfismos del receptor ß 1 y ß 2 adrenérgico como predictor de riesgo de insuficiencia cardiaca crónica

Revista Medica de Chile

Volumn 136, Issue 11, 2008, Pages 1371-1380

  Moraga, Francisco ^a   Troncoso, Rodrigo ^a   Mellado, Rosemarie ^a   Díaz Araya, Guillermo ^a   Vukasovic, José Luis ^b   Greig, Douglas ^c   Pérez, Osvaldo ^c   García, Lorena ^a   Roldán, Juan ^a   Ocaranza, María Paz ^c   Jalil, Jorge ^c   Chiong, Mario ^a   Castro, Pablo ^c  

^a Facultad de Ciencias Químicas y Farmacéuticas   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Catecholamines; Genetic; Heart failure; Polymorphism; Receptors, adrenergic

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 62849085565     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Insel PA. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 1996; 334: 580-585.
2. 1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000; 78: 87-93.
3. 1-adrenergic receptor polymorphisms: analysis of c145AG and c1165GC. Hum Mutat 1999 ;14: 271.
4. 1-adrenergic receptor. J Biol Chem 1999; 274: 12670-74.
5. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-160.
6. 1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21: 1853-8.
7. 1-adrenoceptor: identification and rapid screening assay (letter). Lancet 1999; 353: 897.
8. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 1999; 31: 1025-32.
9. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191-7.
10. 1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935-42.
11. 1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11: 199-205.
12. 1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001; 88: 1034-7.
13. 1-adrenergic receptor gene and hypertension. Circulation 2001; 104: 187-90.
14. 2C adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-42.
15. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to b-blockade. Clin Pharmacol Ther 2003; 73: 366-71.
16. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52.
17. 2-adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000; 161: S197-S201.
18. 2-adrenoceptor polymorphisms and asthma. Monogr Allergy 1996; 33: 153-67.
19. 2-adrenergic receptors desensitize in response to in vivo administered b-agonist. Am J Physiol 1995; 269: L709-L714.
20. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-8.
21. 2-adrenoceptor (ADRB2) haplotypes. A population study. Am J Respir Crit Care Med 1998; 158: 1968-73.
22. 2-adrenoceptor. Hypertension 1997; 30: 773-6.
23. 2-adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int 1998; 53: 1455-60.
24. 2-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension 2001; 37: 286-92.
25. 2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am J Hypertens 2001; 14: 1196-200.
26. Mccaffery JM, Pogue-Geile MF, Ferrell RE, Petro N, Manuck SB. Variability within a- and ß-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens 2002; 20: 1105-14.
27. 2-adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension 2003; 41: 361-7.
28. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268: 23116-21.
29. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-9.
30. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R et al. Beta 1- and beta 2-adrenergicreceptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59: 297-309.
31. 2-adrenoceptors. Circulation 2001; 103: 1048-50.
32. Eichhorn EJ. Prognosis determination in heart failure. Am J Med 2001; 110: 14S-36S.
33. Yancy CW. Clinical trials of beta-blockers in heart failure: a class review. Am J Med 2001; 110: 7S-10S.
34. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac ß-adrenergic receptors, and heart failure. Circulation 2000; 101: 1634-7.
35. Mahon NG, Young JB, Mckenna WJ. Beta adrenergic blockers in chronic congestive cardiac failure: a call for action. Eur J Intern Med 2000; 13: 96-100.
36. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69.
37. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414-9.
38. Dishy V, Sofowara GG, Xie G, Kim RB, Byrne DW, Stein CM et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonistmediated vascular desensitization. N Engl J Med 2001; 345: 1030-5.
39. 1-adrenergic receptor. J Biol Chem 1999; 274: 12670-74.
40. Mialet-Perez JM, Rahtz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9: 1300-5.
41. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004; 117: 451-8.
42. Covolo L, Gelatti U, Metra M, Nodari S, Picciche A, Pezzali N et al. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J 2004; 25: 1534-41.
43. Pacanowski M, Zineh I, Li H, Johnson D, Cooper-Dehoff R et al. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored womens ischemia syndrome evaluation. J Transl Med 2008; 10: 11.
44. Peters RJ, Boekholdt SM. Gene polymorphisms and the risk of myocardial infarction: an emerging relation. N Engl J Med 2002; 347: 1963-5.
45. Wallerstedt SM, Eriksson AL, Ohlsson C, Hedner T. Haplotype association analysisi of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic beta2 receptor in a Swedish hypertensive population. J Hum Hypertens. 2005; 19: 705-8.